CN101670077A - Attenuated compatibility formula of minor Chinese thorowax root decoction - Google Patents

Attenuated compatibility formula of minor Chinese thorowax root decoction Download PDF

Info

Publication number
CN101670077A
CN101670077A CN200810043781A CN200810043781A CN101670077A CN 101670077 A CN101670077 A CN 101670077A CN 200810043781 A CN200810043781 A CN 200810043781A CN 200810043781 A CN200810043781 A CN 200810043781A CN 101670077 A CN101670077 A CN 101670077A
Authority
CN
China
Prior art keywords
minor
radix
portions
chinese thorowax
chinese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200810043781A
Other languages
Chinese (zh)
Inventor
谢天培
戈萌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANJIA BIOLOGICAL MEIDICNE CO Ltd SHANGHAI
Original Assignee
TIANJIA BIOLOGICAL MEIDICNE CO Ltd SHANGHAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANJIA BIOLOGICAL MEIDICNE CO Ltd SHANGHAI filed Critical TIANJIA BIOLOGICAL MEIDICNE CO Ltd SHANGHAI
Priority to CN200810043781A priority Critical patent/CN101670077A/en
Publication of CN101670077A publication Critical patent/CN101670077A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a novel attenuated compatibility formula of a minor Chinese thorowax root decoction. The formula reduces the proportion of a hepatotoxicity medicinal material scutellaria root,increases the proportion of pinellia tuber, and comprises the following components in portion by weight: 2.143 portions of Chinese thorowax root, 1.107 portions of baical skullcap root, 1.107 portionsof ginseng, 2.107 portions of the pinellia tuber, 1.107 portions of ginger, 0.893 portion of liquorice root, and 1.536 portions of Chinese date. Compared with the minor Chinese thorowax root decoction with the original formula in 'Treatise on Cold Pathogenic Diseases' written by Zhang Zhongjing, the remixed minor Chinese thorowax root decoction greatly attenuates the hepatotoxicity and simultaneously keeps the original curative effect of the minor Chinese thorowax root decoction.

Description

Attenuated compatibility formula of minor Chinese thorowax root decoction
Technical field
The present invention relates to the field of Chinese medicines, relate more specifically to a kind of new attenuated compatibility formula of minor Chinese thorowax root decoction.
Background technology
Herba Sidae Rhombifoliae soup comes from treatise on Febrile Diseases, form by Radix Bupleuri, Radix Scutellariae, Radix Ginseng, the Rhizoma Pinelliae, Radix Glycyrrhizae Preparata, Rhizoma Zingiberis Recens, Fructus Jujubae seven flavor medicine, it is the representative prescription for the treatment of SHAO YANG disease by mediation, on clinical department of internal medicine, use very extensive, Herba Sidae Rhombifoliae soup plus-minus treatment digestive system commonly used, blood circulation, respiratory system, urinary system, nervous system disease and psychosis [1]
In recent years the toxin for liver side effect of relevant Herba Sidae Rhombifoliae soup receives increasing concern.External Itoh etc. [Chen Damin. the hepatic injury that the medical herbs Herba Sidae Rhombifoliae soup causes. foreign medical science digestive system disease fascicle 1996; 16 (1): 61-65] report 40 examples are taken the Herba Sidae Rhombifoliae soup patient, there is 9 examples transaminase in the process of taking to raise and jaundice occurs, the hepatic tissue biopsy turns out to be acute liver injury, liver function recovery is normal after the drug withdrawal, hepatic injury appearred again after wherein 4 examples were taken medicine once more, show that Herba Sidae Rhombifoliae soup can bring out acute hepatitis, its mechanism may be relevant with the toxicity of the crude drug of Radix Bupleuri or Radix Scutellariae.It is reported [the gold boat. Japanese Chinese prescription medicine preparation side effect is analyzed. foreign medical science Chinese medicine fascicle 1997; 19 (3): 62-66] [Gan Dianhui, Deng the lady in the moon. the part Chinese herbal medicine causes the report summary [J] of medicamentous liver lesion. the Guangxi Chinese medicine, 2004,6:5-7], Herba Sidae Rhombifoliae soup is widely used in the chronic hepatopathy patient for a long time as the medicine of anti-liver injury, and the result causes acute hepatitis after average 2 months incubation period, the fat-like pathological changes and the fibrosis of the property necrosis of Microscopic examination showed lobules of liver central authorities, microcapsule blister, the performance [3,4] of cholestasis is arranged in two biopsy hepatic tissues.Also there is the scholar to report [Gu Wenjun, Liu Chunhong, Shen Xizhong. the liver toxicity of medical herbs [J]. world's clinical medicine, 2003,24:217-226.] untoward reaction of Herba Sidae Rhombifoliae soup and similar side's extractant thereof, wherein many cases are liver function injury (Herba Sidae Rhombifoliae soup 5 examples, little Radix Bupleuri are closed bavin Piao soup, little Radix Bupleuri adds each 1 example of Radix Platycodonis Shigao Tang).
In view of the research to each single medical material in the Herba Sidae Rhombifoliae soup at present focuses mostly on aspect chemical composition analysis and the pharmacological research,, do not see the research of its intoxicating composition and mechanism of toxication to the rarely seen report of the toxicological study of each single medicine of distinguishing the flavor of.In view of the toxin for liver side effect of Herba Sidae Rhombifoliae soup appearance clinically at present, therefore, the Herba Sidae Rhombifoliae soup composition of prescription of new attenuation need be developed in this area simultaneously, is guaranteeing to reduce its hepatotoxicity greatly on the former powerful basis of Herba Sidae Rhombifoliae soup.
Summary of the invention
The present invention confirms the liver toxicity of Herba Sidae Rhombifoliae soup prescription, and clear and definite causes hepatotoxic medical material in this prescription.
Purpose of the present invention just provides a kind of new attenuated compatibility formula of minor Chinese thorowax root decoction.
In the present invention, provide a kind of Herba Sidae Rhombifoliae soup composition of prescription, medical material and part by weight thereof that this prescription comprises are as follows,
2.143 parts of Radix Bupleuri, 1.107 parts of Radix Scutellariaes, 1.107 parts of Radix Ginsengs, 2.107 parts of the Rhizoma Pinelliaes, 1.107 parts in Rhizoma Zingiberis Recens, 0.893 part in Radix Glycyrrhizae, 1.536 parts in Fructus Jujubae
In another preference, described prescription is to the perform toxic attenuation of liver.
Description of drawings
Fig. 1 mtt assay detects different method for making Herba Sidae Rhombifoliae soup to the active influence of human hepatoma cell strain
Fig. 2 mtt assay detects the different compatibilities side of subtracting decocting liquid to the active influence of human hepatoma cell strain
The specific embodiment
The human liver cell toxicity vitro detection of embodiment 1. different composition of prescription Herba Sidae Rhombifoliae soup
1. material and instrument
1.1 medicine and reagent Radix Bupleuri, Rhizoma Pinelliae Preparata, Radix Glycyrrhizae Preparata, Fructus Jujubae are available from Shanghai Kangqiao Medicinal Materials Electuary Co., Ltd.; Radix Scutellariae is available from Shanghai Dehua National Medicine Products Co., Ltd.; Radix Ginseng is available from decoction pieces factory of German-Chinese medicine company of last Hisense; Rhizoma Zingiberis Recens is purchased in market; Acetaminophen, tamoxifen and tetramethyl azo azoles salt (MTT) are available from Sigma company; RPMI 1640 culture medium and calf serum are available from Gibco company; Penicillin and streptomycin are available from North China pharmaceutical Co. Ltd; Dimethyl sulfoxine (DMSO) is available from Chemical Reagent Co., Ltd., Sinopharm Group.
1.2 cell strain human hepatoma cell strain SMMC-7721 is available from Shanghai cell resource center of the Chinese Academy of Sciences, the normal liver cell is provided by auspicious moral hepatic disease institute (Shanghai).
1.3 instrument superclean bench (Su Jing group), CO2 gas incubator (Thermo Forma), inverted microscope (Chongqing Photoelectric Instruments Corp.), microplate reader (Shanghai Lei Bo Analytical Instrument Co., Ltd), ultrasonic washing instrument (Shanghai High Kudos Science Instrument Co., Ltd.).
1.4 the preparation of medical material decocting liquid and ultrasonic extraction liquid
1.4.1 the former side's decocting of Herba Sidae Rhombifoliae soup liquid (treatise on Febrile Diseases Zhang Zhongjing side) precision takes by weighing Radix Bupleuri 4.286g, Radix Scutellariae 3.214g, and Radix Ginseng 2.143g, Rhizoma Pinelliae Preparata 3.214g, Radix Glycyrrhizae Preparata 1.786g, Rhizoma Zingiberis Recens 3.214g, Fructus Jujubae 2.143g adds 10 times of water gaging 200ml, and infiltration is spent the night; Ebuillition of heated, little the boiling of little fire fried in shallow oil 1h, collects decocting liquid, and 4 layers of filtered through gauze get filtrate; The residue medicinal residues add 8 times of water gaging 160ml, get filtrate with aforementioned extracting method; Merging filtrate, the monolayer filter paper filtering, heating is concentrated into 20ml, and the microporous filter membrane through 0.45 μ m and 0.22 μ m filters respectively.
1.4.2 the Six-element side of subtracting decocting liquid Six-element (no Radix Bupleuri), Six-element (no Radix Scutellariae), Six-element (the no Rhizoma Pinelliae), Six-element (no Radix Ginseng), Six-element (no Radix Glycyrrhizae), Six-element (no Rhizoma Zingiberis Recens), 7 kinds of decocting liquid of Six-element (no Fructus Jujubae), the same 1.4.1 of medical material amount and method for making.
, fry in shallow oil the two flavor side of subtracting decocting liquid Radix Scutellariaes totally 6 kinds of decocting liquid, the same 1.4.1 of medical material amount and method for making 1.4.3 closing with Radix Bupleuri, the Rhizoma Pinelliae, Radix Ginseng, Radix Glycyrrhizae, Rhizoma Zingiberis Recens, Fructus Jujubae respectively.
1.4.4 single medical material decocting liquid Radix Bupleuri, Radix Scutellariae, the Rhizoma Pinelliae, Radix Ginseng, Radix Glycyrrhizae, Rhizoma Zingiberis Recens, 7 kinds of decocting liquid of Fructus Jujubae, the same 1.4.1 of medical material amount and method for making.
1.4.5 former side's ultrasonic extraction liquid precision takes by weighing 1.4.1 medical material amount, adds 5 times of water gaging 100ml, infiltration is spent the night; Ultrasonic 30min, 4 layers of filtered through gauze, the monolayer filter paper filtering, heating is concentrated into 20ml, and the microporous filter membrane through 0.45 μ m and 0.22 μ m filters respectively.
1.4.6 Radix Bupleuri ultrasonic extraction liquid medical material amount and the same 1.4.5 of method for making.
1.4.7 Radix Scutellariae ultrasonic extraction liquid medical material amount and the same 1.4.5 of method for making.
1.4.8 Radix Scutellariae+Radix Bupleuri ultrasonic extraction liquid medical material amount and the same 1.4.5 of method for making.
2. method and result
2.1 all experiment medicines final concentrations in 96 porocyte culture plates of drug solution are respectively 5,10,20,30,40mgml -1(being equivalent to former side's medical material concentration); Positive control is acetaminophen (AAP) (5mmolL -1); Negative control is PBS (phosphate buffer).
2.2 the cytoactive detection method adopts RPMI 1640 culture medium (to contain 10% calf serum, 100Uml -1Penicillin, 100 μ gml -1Streptomycin), with concentration 5 * 10 4Ml -1Human liver cancer cell be inoculated in 96 orifice plates, every hole 200 μ l, in 37 ℃, 5%CO 2Overnight incubation in the incubator.Discard on the plate original liquid in each hole, add the cell culture fluid that contains the respective concentration medicine respectively, 4 multiple holes of the every concentration of every medicine, in 37 ℃, 5%CO 2Cultivate in the incubator.Behind the 24h, add MTT (5mgml -1) 20 μ l/ holes.37 ℃, 5%CO 2After temperature is incubated 4h in the incubator, abandon on the plate original liquid in each hole, add DMSO 200 μ l/ holes and precipitate with Rong Xie Jia Za (formazan).After room temperature is put 30min, under the 570nm wavelength, measure each hole optical density value (OD) with microplate reader.Calculate cytoactive: cytoactive (cell viability, %)=experimental group optical density value/matched group optical density value * 100%.
2.3 homogeneity test of variance and t check are adopted in statistical disposition.Inspection level α=0.1 of homogeneity test of variance, inspection level α=0.05 of t check.
2.4 result
2.4.1 the former side's decocting of Herba Sidae Rhombifoliae soup liquid has remarkable inhibition to human hepatoma cell strain growth, the former side's decocting of Herba Sidae Rhombifoliae soup liquid 20,30,40mgml -1The cell relative activity of concentration group is respectively 66.3%, 50.1% and 35.1% (Fig. 1, table 1);
2.4.2 former side and Radix Bupleuri ultrasonic extraction liquid do not have remarkable inhibition, Radix Scutellariae, Radix Scutellariae+Radix Bupleuri ultrasonic extraction liquid have remarkable inhibition (Fig. 1, table 1);
2.4.3 in the Six-element side of the subtracting decocting liquid, the decocting liquid that does not contain Radix Scutellariae does not have remarkable inhibition, other the 6 kinds decocting liquid that contain Radix Scutellariae all have remarkable inhibition (Fig. 2, table 2);
2.4.4 in the single medicinal material decocting liquid, only Radix Scutellariae has remarkable inhibition, other 6 kinds of single medicinal materials all do not have remarkable inhibitory action (Fig. 2, table 2);
2.4.5 in the two flavor side of the subtracting decocting liquid, only Radix Scutellariae+Rhizoma Pinelliae closes decocting liquid does not have remarkable inhibition, other 5 kinds all have remarkable inhibitory action, wherein the inhibitory action of Radix Scutellariae+Radix Bupleuri is the strongest, the cell relative activity of its each concentration group all is lower than the cell relative activity that Radix Scutellariae, Radix Bupleuri are done the time spent respectively separately, prompting Radix Bupleuri may and strengthen the toxicity (Fig. 2, table 2) of Radix Scutellariae with the Radix Scutellariae synergism.
Table 1 mtt assay detect the 570nm optical density value (OD value) that the former side of Herba Sidae Rhombifoliae soup, Radix Bupleuri, Radix Scutellariae, Radix Scutellariae+Radix Bupleuri ultrasonic extraction liquid act on human hepatoma cell strain (x ± s, n=4)
Figure A20081004378100061
Figure A20081004378100062
Annotate: *P<0.05, *P<0.01
Table 2 mtt assay detect the 570nm optical density value (OD value) that the former side of Herba Sidae Rhombifoliae soup, the Six-element side of subtracting, the two flavor sides of subtracting and each single medical material decocting liquid acts on human hepatoma cell strain (x ± s, n=4)
Figure A20081004378100071
Figure A20081004378100081
Annotate: *P<0.05, *P<0.01
Embodiment 2. is the human liver cell toxicity vitro detection of the Herba Sidae Rhombifoliae soup of composition of prescription again
Again reduced the ratio of liver toxicity medical material Radix Scutellariae in the prescription of compatibility, increased the ratio of the Rhizoma Pinelliae, the proportion of composing of each medical material was as follows during new group was put:
2.143 parts of Radix Bupleuri, 1.107 parts of Radix Scutellariaes, 1.107 parts of Radix Ginsengs, 2.107 parts of the Rhizoma Pinelliaes, 1.107 parts in Rhizoma Zingiberis Recens, 0.893 part in Radix Glycyrrhizae, 1.536 parts in Fructus Jujubae.
Method among the employing embodiment 1 is carried out mtt assay and is detected again the effect of the Herba Sidae Rhombifoliae soup decocting liquid of compatibility to the human liver cell strain, the Herba Sidae Rhombifoliae soup that the result shows again compatibility weakens greatly than the toxicity of the former side's Herba Sidae Rhombifoliae soup of treatise on Febrile Diseases Zhang Zhongjing, has kept the original curative effect of Herba Sidae Rhombifoliae soup simultaneously.

Claims (2)

1. a Herba Sidae Rhombifoliae soup composition of prescription is characterized in that, the medical material and the part by weight thereof that comprise are as follows,
2.143 parts of Radix Bupleuri, 1.107 parts of Radix Scutellariaes, 1.107 parts of Radix Ginsengs, 2.107 parts of the Rhizoma Pinelliaes, 1.107 parts in Rhizoma Zingiberis Recens, 0.893 part in Radix Glycyrrhizae, 1.536 parts in Fructus Jujubae
2. Herba Sidae Rhombifoliae soup composition of prescription as claimed in claim 1 is characterized in that this prescription is to the perform toxic attenuation of liver.
CN200810043781A 2008-09-12 2008-09-12 Attenuated compatibility formula of minor Chinese thorowax root decoction Pending CN101670077A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200810043781A CN101670077A (en) 2008-09-12 2008-09-12 Attenuated compatibility formula of minor Chinese thorowax root decoction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200810043781A CN101670077A (en) 2008-09-12 2008-09-12 Attenuated compatibility formula of minor Chinese thorowax root decoction

Publications (1)

Publication Number Publication Date
CN101670077A true CN101670077A (en) 2010-03-17

Family

ID=42017633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200810043781A Pending CN101670077A (en) 2008-09-12 2008-09-12 Attenuated compatibility formula of minor Chinese thorowax root decoction

Country Status (1)

Country Link
CN (1) CN101670077A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102488874A (en) * 2011-12-14 2012-06-13 哈药集团中药二厂 Method for preparing bupleurum and cassia twig freeze-dried oral preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102488874A (en) * 2011-12-14 2012-06-13 哈药集团中药二厂 Method for preparing bupleurum and cassia twig freeze-dried oral preparation

Similar Documents

Publication Publication Date Title
TWI324069B (en) Herbal composition phy906 and its use in chemotherapy
CN111150792A (en) Chinese medicinal composition with effect of resisting novel coronavirus SARS-Cov-2, and preparation method and application thereof
CN103127321A (en) Traditional Chinese medicine composition for treating prostatitis and preparation method thereof
CN101757386B (en) Preparation method of traditional Chinese medicine for treating infantile capillary bronchitis
CN101391042B (en) Traditional Chinese medicine extract for suppressing lung cancer A549 cell proliferation and preparation method thereof
CN103142842B (en) Traditional Chinese medicine for treating diabetes mellitus
CN101940642B (en) Chinese medicinal composition and application thereof
CN101505779A (en) A hypolipidemic composition and its use
CN111632116A (en) Preparation method of traditional Chinese medicine preparation for resisting viral cold
CN101670077A (en) Attenuated compatibility formula of minor Chinese thorowax root decoction
CN101342249B (en) Chinese medicine formulations for treating hepatitis B and preparation method thereof
CN103690768B (en) Join stilbene soft capsule and preparation method thereof the tuber of dwarf lilyturf
CN1899415B (en) Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method
CN102772732B (en) Medicine composition for treating chronic liver disease
CN101695562B (en) Chinese medicinal composition for treating viral hepatitis and preparation method thereof
CN105267559A (en) Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof
CN103463244A (en) Method for extracting blood sugar lowering substance from China roses and application of blood sugar lowering substance
CN104367673B (en) A kind of Chinese medicine composition treating Eimeria species
CN102240328B (en) Traditional Chinese medicine for treating cold and preparation method thereof
CN102697800B (en) Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof
Chandil et al. In-vitro study of CO2 extract of Terminalia chebula in breast cancer cell line md-mba-231
CN105412646B (en) A kind of Chinese medicine composition and application thereof for treating fever caused by exogenous pathogens
CN105106914B (en) A kind of small radix bupleuri sustained-release tablet and preparation method thereof
CN108159377A (en) A kind of Chinese medicine preparation for anti-trioxypurine
CN107898972A (en) A kind of Chinese medicine composition and application for being used to treat liver diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100317